|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: LPL |
Gene summary for LPL |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | LPL | Gene ID | 4023 |
| Gene name | lipoprotein lipase | |
| Gene Alias | HDLCQ11 | |
| Cytomap | 8p21.3 | |
| Gene Type | protein-coding | GO ID | GO:0001816 | UniProtAcc | A0A1B1RVA9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4023 | LPL | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 2.29e-03 | 4.08e-02 | -0.2116 |
| 4023 | LPL | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 2.36e-05 | -5.78e-01 | -0.0166 |
| 4023 | LPL | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 1.37e-03 | -5.63e-01 | -0.0132 |
| 4023 | LPL | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 5.69e-03 | -5.50e-01 | -0.013 |
| 4023 | LPL | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 1.36e-05 | -5.78e-01 | -0.0121 |
| 4023 | LPL | male-WTA | Human | Thyroid | PTC | 3.77e-15 | 2.04e-01 | 0.1037 |
| 4023 | LPL | PTC01 | Human | Thyroid | PTC | 2.66e-05 | 1.47e-01 | 0.1899 |
| 4023 | LPL | PTC04 | Human | Thyroid | PTC | 1.25e-05 | 2.52e-01 | 0.1927 |
| 4023 | LPL | PTC06 | Human | Thyroid | PTC | 1.81e-25 | 8.61e-01 | 0.2057 |
| 4023 | LPL | PTC07 | Human | Thyroid | PTC | 3.77e-15 | 5.29e-01 | 0.2044 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0090150110 | Esophagus | ESCC | establishment of protein localization to membrane | 182/8552 | 260/18723 | 1.27e-15 | 8.19e-14 | 182 |
| GO:0072659110 | Esophagus | ESCC | protein localization to plasma membrane | 193/8552 | 284/18723 | 1.95e-14 | 1.03e-12 | 193 |
| GO:199077819 | Esophagus | ESCC | protein localization to cell periphery | 217/8552 | 333/18723 | 4.08e-13 | 1.88e-11 | 217 |
| GO:0031667111 | Esophagus | ESCC | response to nutrient levels | 289/8552 | 474/18723 | 9.25e-12 | 3.47e-10 | 289 |
| GO:001631110 | Esophagus | ESCC | dephosphorylation | 251/8552 | 417/18723 | 1.26e-09 | 2.99e-08 | 251 |
| GO:0048545111 | Esophagus | ESCC | response to steroid hormone | 204/8552 | 339/18723 | 4.47e-08 | 8.11e-07 | 204 |
| GO:000758410 | Esophagus | ESCC | response to nutrient | 114/8552 | 174/18723 | 9.43e-08 | 1.56e-06 | 114 |
| GO:000206420 | Esophagus | ESCC | epithelial cell development | 136/8552 | 220/18723 | 9.50e-07 | 1.21e-05 | 136 |
| GO:000164918 | Esophagus | ESCC | osteoblast differentiation | 140/8552 | 229/18723 | 1.63e-06 | 1.95e-05 | 140 |
| GO:000150317 | Esophagus | ESCC | ossification | 232/8552 | 408/18723 | 3.00e-06 | 3.40e-05 | 232 |
| GO:006195114 | Esophagus | ESCC | establishment of protein localization to plasma membrane | 44/8552 | 60/18723 | 1.25e-05 | 1.15e-04 | 44 |
| GO:003249619 | Esophagus | ESCC | response to lipopolysaccharide | 191/8552 | 343/18723 | 1.11e-04 | 7.73e-04 | 191 |
| GO:00332734 | Esophagus | ESCC | response to vitamin | 60/8552 | 93/18723 | 1.89e-04 | 1.21e-03 | 60 |
| GO:00466774 | Esophagus | ESCC | response to antibiotic | 34/8552 | 47/18723 | 1.91e-04 | 1.21e-03 | 34 |
| GO:000223719 | Esophagus | ESCC | response to molecule of bacterial origin | 194/8552 | 363/18723 | 1.64e-03 | 7.61e-03 | 194 |
| GO:00603485 | Esophagus | ESCC | bone development | 115/8552 | 205/18723 | 1.67e-03 | 7.72e-03 | 115 |
| GO:0033280 | Esophagus | ESCC | response to vitamin D | 25/8552 | 35/18723 | 1.82e-03 | 8.35e-03 | 25 |
| GO:003196020 | Esophagus | ESCC | response to corticosteroid | 95/8552 | 167/18723 | 2.27e-03 | 9.99e-03 | 95 |
| GO:005138420 | Esophagus | ESCC | response to glucocorticoid | 85/8552 | 148/18723 | 2.60e-03 | 1.11e-02 | 85 |
| GO:00487052 | Esophagus | ESCC | skeletal system morphogenesis | 120/8552 | 220/18723 | 4.90e-03 | 1.89e-02 | 120 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| LPL | SNV | Missense_Mutation | novel | c.817C>T | p.His273Tyr | p.H273Y | P06858 | protein_coding | deleterious(0.03) | probably_damaging(0.991) | TCGA-BH-A0BW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin | CR |
| LPL | SNV | Missense_Mutation | novel | c.146C>T | p.Thr49Ile | p.T49I | P06858 | protein_coding | tolerated(0.1) | benign(0.012) | TCGA-E2-A14V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
| LPL | insertion | Frame_Shift_Ins | novel | c.1050_1051insTCTCCTAGGCTGGAGGAGA | p.Gly351SerfsTer9 | p.G351Sfs*9 | P06858 | protein_coding | TCGA-BH-A0B8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | ||
| LPL | SNV | Missense_Mutation | rs557015233 | c.112N>A | p.Glu38Lys | p.E38K | P06858 | protein_coding | tolerated(0.31) | benign(0.202) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| LPL | SNV | Missense_Mutation | rs199675233 | c.373N>A | p.Ala125Thr | p.A125T | P06858 | protein_coding | deleterious(0.02) | probably_damaging(0.982) | TCGA-EK-A2PI-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
| LPL | SNV | Missense_Mutation | c.1120N>C | p.Glu374Gln | p.E374Q | P06858 | protein_coding | tolerated(0.38) | possibly_damaging(0.673) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| LPL | SNV | Missense_Mutation | c.277N>T | p.Pro93Ser | p.P93S | P06858 | protein_coding | tolerated(0.4) | possibly_damaging(0.678) | TCGA-AA-3713-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | PR | |
| LPL | SNV | Missense_Mutation | c.1213N>G | p.Leu405Val | p.L405V | P06858 | protein_coding | tolerated(0.47) | benign(0.029) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| LPL | SNV | Missense_Mutation | c.1423G>T | p.Gly475Cys | p.G475C | P06858 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.971) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| LPL | SNV | Missense_Mutation | c.1344N>T | p.Glu448Asp | p.E448D | P06858 | protein_coding | tolerated(1) | benign(0.005) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 4023 | LPL | DRUGGABLE GENOME, LIPASE, PHOSPHOLIPASE, CELL SURFACE | INSULIN | INSULIN | 15202783,8727949 | |
| 4023 | LPL | DRUGGABLE GENOME, LIPASE, PHOSPHOLIPASE, CELL SURFACE | NADOLOL | NADOLOL | 1681747 | |
| 4023 | LPL | DRUGGABLE GENOME, LIPASE, PHOSPHOLIPASE, CELL SURFACE | LAK | 8895065 | ||
| 4023 | LPL | DRUGGABLE GENOME, LIPASE, PHOSPHOLIPASE, CELL SURFACE | ACARBOSE | ACARBOSE | 8886823 | |
| 4023 | LPL | DRUGGABLE GENOME, LIPASE, PHOSPHOLIPASE, CELL SURFACE | Ibrolipim | IBROLIPIM | ||
| 4023 | LPL | DRUGGABLE GENOME, LIPASE, PHOSPHOLIPASE, CELL SURFACE | fenofibrate | FENOFIBRATE | 19207029 | |
| 4023 | LPL | DRUGGABLE GENOME, LIPASE, PHOSPHOLIPASE, CELL SURFACE | Gemfibrozil | GEMFIBROZIL | ||
| 4023 | LPL | DRUGGABLE GENOME, LIPASE, PHOSPHOLIPASE, CELL SURFACE | RU 486 | 7627771 | ||
| 4023 | LPL | DRUGGABLE GENOME, LIPASE, PHOSPHOLIPASE, CELL SURFACE | L-ASPARAGINASE | ASPARAGINASE | 9264396 | |
| 4023 | LPL | DRUGGABLE GENOME, LIPASE, PHOSPHOLIPASE, CELL SURFACE | DIAZOXIDE | DIAZOXIDE | 14499880 |
| Page: 1 2 3 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |